Aastrom builds on stem cell success in heart failure
This article was originally published in Scrip
Aastrom Bioscience's stem cell treatment ixmyelocel-T has improved heart function in a Phase IIa study in patients with heart failure due to dilated cardiomyopathy.
You may also be interested in...
A new analysis of the ADAURA study shows that Tagrisso’s disease-free survival benefits in early stage EGFRm NSCLC are replicated for brain metastases, a common complication with a poor prognosis. Filings and OS data await.
Further competition to Sanofi/Regeneron’s Dupixent in nasal polyps is on the horizon but the newcomers will have some catching up to do.
A 39% relative risk reduction in the primary endpoint for the DAPA-CKD study and a 31% reduction in all-cause mortality prime Farxiga for a new chronic kidney disease indication following filings due in the next few months.